Condition 1: Thyroid gland. Condition 2: Prediabetes. Disorders of thyroid gland Impaired glucose tolerance
Conditions
Interventions
Intervention 1: One group will receive placebo with a sercret code.
(Subjects were instructed to take 1 tablet 500 mg placebo daily. But in the 1st week, subjects were instructed to take 2 tablet
Placebo
Treatment - Drugs
One group will receive placebo with a sercret code.
(Subjects were instructed to take 1 tablet 500 mg placebo daily. But in the 1st week, subjects were instructed to take 2 tablet 500 mg daily,
The other group will receive metformin with a secret code. (Subjects were instructed to take 1 tablet 500 mg Metformin daily. But in the 1st week, subjects were instructed to take 2 tablet 500 mg dail
Sponsors
Isfahan Endocrine and Metabolism Research Center
Raha Pharmaceutical Company
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria :patients with pre-diabetes [Impaired fasting plasma glucose (100 to 125 mg/dl) or impaired glucose tolerance (IGT) (2-h PG OGTT values of 140–199 mg/dL and having 18 to 65 years old] were initially included. Exclusion criteria: Those patients with thyroid malignancy or any other malignancy; previous-thyroxin suppression therapy at any time; obesity due to endocrine disease; Pregnancy and lactation; renal failure or liver failure; neurological or psychological disorders (depression, epilepsy, schizophrenia); heart failure; hypothyroidism or hyperthyroidism; smoking and finally iodinated contrast material exposure in the previous 6 months ago all were excluded from the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thyroid Stimulating Hormone. Timepoint: Baseline and 3 months later. Method of measurement: TSH : were performed using immunoassay system by an automated analyzer Siemens 2010 (ADVIA Centaur CP Immunoassay System).;Thyroid volume. Timepoint: Before and after 3 months treatment. Method of measurement: Thyroid ultrasonography was performed by single physician, who was unaware of the patients’ any clinical conditions, using a 7 - 9 MHz linear probe ( Logiq 500 Pro, GE Medical Systems, WI, USA). | — |
Secondary
| Measure | Time frame |
|---|---|
| Thyroid Nodule. Timepoint: Baseline and 3 months later. Method of measurement: Thyroid ultrasound by logic 500 general electric probe 7-9.;IR=Homeostasis Model Assessment Of Insulin Resistance. Timepoint: Baseline and 3 months later. Method of measurement: HOMA-IR ={ Insulin(mU/L) × Fasting Blood glucose(mmol/L)}÷22.5. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMozhgan karimifar
Isfahan Endocrine and Metabolism Research Center
Outcome results
None listed